The idea of collecting blood on a paper card and subsequently using the dried blood spots (DBS) for diagnostic purposes originated a century ago. Since then, DBS testing for decades has remained predominantly focused on the diagnosis of infectious diseases especially in resourcelimited settings or the systematic screening of newborns for inherited metabolic disorders and only recently have a variety of new and innovative DBS applications begun to emerge. For many years, pre-analytical variables were only inappropriately considered in the field of DBS testing and even today, with the exception of newborn screening, the entire pre-analytical phase, which comprises the preparation and processing of DBS for their final analysis has not been standardized. Given this background, a comprehensive step-by-step protocol, which covers al the essential phases, is proposed, i.e., collection of blood; preparation of blood spots; drying of blood spots; storage and transportation of DBS; elution of DBS, and finally analyses of DBS eluates. The effectiveness of this protocol was first evaluated with 1,762 coupled serum/DBS pairs for detecting markers of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infections on an automated analytical platform. In a second step, the protocol was utilized during a pilot study, which was conducted on active drug users in the German cities of Berlin and Essen.
Introduction
The idea of using blood collected on a paper card made of cellulose is ascribed to Ivar Christian Bang (1869 Bang ( -1918 , the father of modern clinical microanalysis 1, 2 . In 1913, Bang determined glucose from eluates of dried blood spots (DBS) 3 and, later, also performed nitrogen measurements using the Kjeldahl method with this filter paper technique 2 . Subsequently, several investigators reported on the use of DBS for serological testing to diagnose syphilis 2 . As early as in 1924, Chapman summarized the advantages of DBS testing when he particularly stressed four items, which are still valid today: (1) compared to conventional venipuncture, less blood volume is required and this fact was most important in pediatric diagnostics; (2) blood collection is simple, non invasive, and inexpensive; (3) the risk of bacterial contamination or hemolysis is minimal; and (4) DBS can be preserved for long periods with almost no deterioration of the analytes 2, 4 . Besides its use in testing for syphilis, further early applications of the DBS technique included, e.g., the detection of antibodies against measles, mumps, poliovirus, parainfluenza virus, and respiratory syncytial virus (RSV) in 1953 2 , the identification of Shigella in feces dried onto filter paper and shipped by regular mail from Indonesia to Leiden in the Netherlands as well as the detection of antibodies to Schistosoma in DBS taken in endemic areas and analyzed more than three months later 5 . In 1963, fifty years after Bang's original communication 2, 6 , Guthrie finally published his famous method for the diagnosis of phenylketonuria from DBS obtained by a heel prick from newborns 7, 8 .
Although from that time onwards, DBS were regarded as a commonly applicable method for collecting, storing, transporting, and analyzing a variety of human body fluids 5 , their use in diagnostics still remained predominantly focused on the diagnosis of infections especially in resourcelimited settings and the systematic screening of newborns for inherited metabolic disorders for decades 9, 10 . Since 2005, however, a variety of new and innovative DBS applications have begun to emerge. This resulted in an almost exponential increase in the number of respective scientific publications on DBS from about 50 to almost 450 annually at present. Among the emerging applications are such diverse fields as toxico-and pharmacokinetic studies, metabolic profiling, therapeutic drug monitoring, forensic toxicology, or environmental contamination control 10, 11 . DBS testing has, thus, made a triumphal march through clinical laboratory diagnostics during the past 100 years 2 . As in clinical chemistry 12 , however, during this march pre-analytical variables were not adequately considered for many years. Indeed, even today, after such eminent activities as the CDC's filter paper evaluation project 13 or the formulation of a national standard for blood collection on filter paper in the framework of newborn screening 14 . In a second step, the protocol was utilized in the pilot study "Drugs and Chronic Infectious Diseases" ("DRUCK Study") which was conducted by the Robert Koch-Institute in close collaboration with the National Reference Centre for Hepatitis C on active drug users in the German cities of Berlin and Essen
18
.
Protocol
Since the protocol is designed for use in medical diagnostics, its application must follow the principles of the Declaration of Helsinki 19 . For the first part of the results presented in this communication, both a separate agreement by the patients and approval by an ethics committee seemed to be dispensable for two reasons: (1) "Upon admission" to Essen University hospital, "every patient provides written consent to all necessary biochemical, bacteriological, and virological investigations." 17 (2) "All samples used throughout the evaluation of DBS testing were sent to the Institute of Virology in the process of routine clinical diagnostics. Thus, none of the specimens was collected specifically for the purpose of the study, not a single additional venipuncture was performed and none of the materials was tested for any parameter other than those required by the physicians in the course of the normal diagnostic work-up." 17 The study "Drugs and Chronic Infectious Diseases" (DRUCK Study") 18 , in which DBS testing was finally used in the German cities of Berlin and Essen to evaluate people who actively inject drugs, was approved by the Federal Commissioner for Data Protection and Freedom of Information (Berlin, Germany) and as well as by the ethics committee of the Medical University Charité, (Berlin, Germany).
Drying of Blood Spots
1. To dry the blood spots, put the filter cards on a clean paper towel in a biohazard safety cabinet and let them dry, preferably O/N (but for at least 4 hrs), at RT in the absence of any external source of heat. When the drying process is complete, the blood spots have a uniformly dark brownish color and no red areas are visible anymore ( Figure 1D ) 13, 15, 16 .
Storage and Transportation of Dried Blood Spots (DBS)
NOTE: Processing of the blood spots can be interrupted after drying. The filter cards can now be stored 13 -16, 23 .
1. For storage, put the filter paper card in a single, gas-impermeable zipper bag, containing 1 to 2 desiccant sachets to protect the specimens from moisture ( Figure 1E) Figure 1G ). Adapt the volume of added buffer to the minimal respective requirements of the assay used for subsequent analysis of dried blood spots eluates. 3. Repeat these steps to obtain a second series of dried blood spot eluates in order to perform molecular analyses. 4. Put the cell culture plate on a laboratory shaker and let the punched dried blood spots gently elute for a minimum of 4 hr or, preferably, O/ N ( Figure 1H ). 5. The next day, the spots are almost free from blood and hemolytic supernatants have formed ( Figure 1I ). Transfer these eluates to microcentrifuge tubes. Then, subject them to centrifugation for 2 min at 10,500 x g ( Figure 1J ) to free the supernatants from any debris that had formed during elution ( Figure 1K ). . When drying of the blood spots is complete and storage is necessary, the filter cards can be packaged in gas-impermeable zipper bags containing 1 -2 desiccant sachets (E). Further laboratory processing of DBS comprise the generation of punches by a 6 mm single use device from the center of the circles (F, G), the elution of the punches in a PBS-based buffer for a minimum of 4 hr or, preferably, O/N on a shaker (H), the recovery of the eluates (I), and finally centrifugation of the laboratory cups (J) to free the DBS eluates from any debris that might have originated during the elution process (K). Subsequently, the DBS eluates are ready for analyses, which were performed by a fully automated platform (L) in order to detect serological markers of HBV, HCV and HIV infections, respectively. Please click here to view a larger version of this figure.
Analysis of Eluates

Representative Results
The effectiveness of the protocol suggested for preparation and processing of DBS was first evaluated by analyzing 1,762 coupled serum/DBS pairs for markers of HBV, HCV, and HIV infection. 17 . For this purpose, DBS were prepared from 100 µl whole venous blood (cf. points 2.1.1 -2.1.6 of the preceding protocol) and were eluted with 1,000 µl of PBS-based buffer, each, (cf. points 5.1 -5.5 of the aforementioned protocol) to complete the process for all seven parameters in two separate operations. Such an approach without careful optimization of the elution conditions for every single analyte seemed to be unavoidable because a rather high sample throughput was expected in a comparatively short time during the forthcoming field study "Drugs and Chronic Infectious Diseases" ("DRUCK Study").
All measurements adhered to the manufacturer's recommendations in the course of DBS analyses but had to be modified with respect to HBsAg and anti-HBs determinations to compensate either for the effect of hemolysis or the result of dilution. With a cut-off value of 0.05 IU/ ml, HBsAg testing of DBS eluates lead to a rate of false-positives of 14.7% (52 out of 354) when compared to the serum samples (Figure 2A) . Receiver operating characteristic (ROC) analysis 25, 26 of the data indicated that an increase of the threshold to 0.15 IU/ml would result in an ideal separation of HBsAg-positives from HBsAg-negatives (0.986 [sensitivity], 0.000 [1-specificity], Figure 2B ). On the other hand, with a cut-off of 10 IU/l for quantification of anti-HBs antibodies a rate of false-negative measurements of 14.2 % (47 out of 331) was recorded ( Figure 2C) . Hence, following ROC analysis again, this cut-off was lowered to 1.5 IU/l to achieve an optimal discrimination of values (0.917 [sensitivity], 0.007 [1-specificity], Figure 2D ). The results of the coupled serum/DBS analyses are summarized in Table 1 17 .No non-specificity was recorded in the course of DBS testing for any of the seven analytes.
When DBS eluates were investigated for the presence of HBsAg, i. e. the serological key parameter of both acute and chronic infection with HBV, an analytical sensitivity of 98.6 % was determined. HBsAg concentrations in the two falsely-negative sera were 749 IU/ml and 6 IU/ml, respectively. Anti-HBc antibodies were successfully detected in 176 out of 204 (i. e 86.3 %) DBS eluates. Twenty-two out of the 28 specimens which were not detected by the measurements originated from individuals co-infected with HIV. Thus, if HIV-positive individuals were excluded from the calculation, a sensitivity of 97.1 % was achieved for retrieving anti-HBc antibodies from eluted dried whole venous blood. Similar observations held true for the determination of anti-HBs antibodies. Even after adjustment of the cut-off value of the assay to 1.5 IU/l, nine discrepant serum DBS results occurred. In the patients not co-infected with HIV, serum anti-HBs concentrations of 11 -26 IU/l were found, which were too low to allow for detection after elution of the dried blood.
Anti-HCV antibodies are indicative of either an acute or chronic or resolved infection. Only four (i. e. 2.2 %) falsely-negative anti-HCV results were determined from DBS eluates and further serological and molecular analyses clearly demonstrated that the respective sera were very probably taken from patients, whose infections had long since been resolved.
The detection of anti-HIV antibodies in DBS eluates with the fully automated system was a completely smooth process which yielded an analytical sensitivity of 100 %.
"Mean HBV DNA concentration from whole blood eluates was performed on 100 specimens (mean DNA concentration: 1,573,898 IU/ml, range: < 357 -> 17,860,000 IU/ml) and yielded a value of 93.0 %. Thus, seven samples with low serum HBV DNA concentrations between 409 and 3,643 IU/ml were not detected by the DBS testing. Of 100 sera which had proven to be HCV RNA positive (mean HCV RNA concentration: 1,415,944 IU/ml, range: 2,479 ->7,692,000 IU/ml), corresponding whole blood aliquots were available. The comparative investigation resulted in an analytical sensitivity of 100 % for HCV RNA determinations from DBS eluates. To test the outlined protocol for preparing and processing DBS under field conditions, it was used in close collaboration with the Robert KochInstitute (Berlin, Germany) during the pilot phase of the study "Drugs and Chronic Infectious Diseases", which was conducted on active drug users in the German cities of Berlin and Essen 18 . All 534 participants enrolled (433 men and 101 women) underwent capillary blood sampling as described in detail in sections 2.2.1 -2.2.3 of the preceding protocol, and DBS were, again, eluted by addition of 1,000 µl of PBS-based buffer.
Two individuals were diagnosed to be chronically infected with HBV, and 39 showed the serological pattern of a resolved HBV infection. Furthermore, fifteen participants were positive for anti-HBs (status after vaccination) and eight were found to be positive for anti-HBc alone. The anti-HCV prevalence among the participants was 57. The results obtained by DBS testing were carefully compared with the study participants' anamnestic data regarding the self-reported HBV and HCV status. This comparison in conjunction with the results of testing coupled serum/DBS pairs led to minor modifications of the testing algorithm for the main phase of the "DRUCK Study", which will enrol active drug users in six additional large German cities: "Individuals infected with HIV will be always tested for the presence of HBV DNA. Participants whose DBS eluates are positive for anti-HBc or anti-HBs should be subjected to a venipuncture during a second consultation in order to definitely clarify their anti-HBc/anti-HBs status and, finally, all DBS eluates will be screened for HCV RNA regardless of the results of anti-HCV testing." 
Anti-HBc 305 28
In serum, twenty-two patients had a resolved HBV infection. Six individuals showed the serological finding "anti-HBc alone". Twentytwo of the patients were coinfected with HIV. From the "HBV resolvers", twenty were assessed as "anti-HBs positive alone" by DBS testing and, thus, were falsely classified as "condition after vaccination".
Anti-HBs 310 9
The four patients not co-infected with HIV had serum anti-HBs concentrations of 11 # 26 IU/l, which were too low to allow for antibody detection after elution of the dried blood spots.
HBV DNA 150 7
The respective sera had been obtained from seven patients with low serum HBV DNA concentrations ranging from 409 IU/ml to 3,643 IU/ml. Table 1 : Results obtained from 1,762 DBS, which were prepared and processed from whole venous blood following the protocol proposed in this communication, compared to the findings in coupled serum samples as a reference.
. To overcome this remarkable heterogeneity, a comprehensive step-by-step instruction for preparing and processing DBS to be utilized in immunoassays and by molecular techniques is presented in this communication and evaluated with regard to its effectiveness for detecting markers of HBV, HCV and HIV infections. The focus of the following discussion is primarily placed on the different steps of the suggested protocol.
In the history of DBS testing many different filter paper cards have been used 2 but today only two commercial sources are approved by the FDA as class II medical devices for blood collection 5, 16 . These filter card systems are highly uniform and have very similar absorption characteristics so that analytical results obtained from capillary blood prepared on either of them do not differ by more than 4% -5% 28 . Not surprisingly, Masciotra and co-workers 29 therefore detected HIV-1 RNA equally well with a qualitative assay after elution from blood collection cards from different sources. Given these data, it can be virtually excluded that any of the discrepancies observed when testing coupled serum/DBS pairs for markers of HBV, HCV and HIV infections 17 was caused by the choice of the filter card alone. However, when accurate quantification of an analyte is indispensable, source-to-source variation may no longer be negligible and more sophisticated techniques, e.g., perforated DBS (PDBS) as a method for microsampling 30 or the preparation of dried serum spots (DSS) 31 may have to be applied instead of conventional DBS testing 10 .
Since only small quantities of blood are used for DBS testing (one drop of capillary blood consists of approximately 50 µl) 5, 16 , variations in the sample volume are crucial and, admittedly, at least some of the discrepancies between serological results and participant's self-reported HBV and HCV status recorded during the piloting of the "DRUCK Study" are attributable to this variable. The single most important factor for minimizing "fluctuations" of the sample volume is undoubtedly a correct technique of capillary blood collection, which can only be achieved by careful and ongoing training of the technical personnel 22 . Furthermore, as a measure of quality control, all laboratories working with DBS should have already initiated procedures for identifying and subsequently excluding DBS specimens that have to be considered as unsatisfactory or invalid 16 .
Studies conducted primarily in the context of HIV 32 and newborn screening 33 have shown that high humidity may lead to a degradation of analytes, but hitherto no consensus has been reached regarding the question of how long DBS should be air-dried. An interval of at least 4 hr or preferably O/N is proposed in this communication, which therefore adopted conditions that were used in the vast majority of all relevant publications 32, 34 Data on storage of DBS to be subsequently used for HBV and HCV testing are conflicting. In 1981, Villa and co-workers 35 , who applied contemporary analytical techniques, reported that storage at RT did not affect the results of HBV analyses during the entire observation period of 180 days if antibody titers were > 1/1,000, but that DBS became borderline-positive or even negative after 15 days when titers in serum were only 1/100. Storage at -20 °C or 4 °C did not result in a substantial improvement. In contrast, a study conducted thirty years later 36 tested
replicates of a HBV-positive sample, and the authors found that anti-HBc as well as anti-HBs antibodies were stable for up to 183 days at RT, whereas HBsAg under the same conditions became false-negative already after 63 days. With regard to HBV DNA detection from DBS eluates, the concentration of the viral nucleic acid was stable for at least seven days at 37 °C 37 or proved to be "resistant" to storage at RT for up to three weeks 38 . Testing for anti-HCV antibodies using two commercially available third generation immunoassays 39 provided accurate results for a period of 117 days using DBS samples stored at -20 °C, 2 -8 °C, and 20 -25 °C, respectively. Storage at -20 °C, however, resulted in the lowest variation of optical densities. Applying a fourth generation anti-HCV ELISA, i.e., Monolisa HCV-Ag-Ab-ULTRA, in the context of DBS testing, Larrat et al. 40 observed a sharp decrease in analytical specificity after storing the DBS specimens for more than three days at RT. On the other hand, precise testing results were obtained with the same kit utilizing samples deposited for 60 days under various conditions (-20 °C, 2 -8 °C, and 22 -26 °C) by Brandao and co-workers 41 . Observations on the decline of HCV RNA concentrations in DBS under various storage conditions range from no significant alteration at RT for up to one year 42 to a tenfold change after four weeks at ambient temperature 43 . Taking this rather conflicting data on the stability of HBV and HCV antigens, nucleic acids and antibodies into account, it seemed reasonable to retract in the proposed protocol to a consensus, which was defined earlier for the storage of DBS specimens to be used for HIV testing 15, 30 : For shortterm deposition (up to two weeks) antigens, viral nucleic acid, and antibodies are regarded as stable at RT, whereas optimal storage for longer periods is at frozen conditions. As a rule, three parameters should be considered when designing an elution protocol: (1) the elution buffer; (2) the duration and temperature of elution; and (3) the elution volume 23 . In the vast majority of all relevant publications phosphate-buffered saline (PBS) was used for eluting DBS, and most authors added a protein, e.g., bovine serum albumin (BSA) or Tween 20, a surfactant, in order to improve the assay signal by stabilizing proteins, as they go into solution, and simultaneously blocking non-specific binding sites 23 . Only a few reports, which directly compare different elution buffers in the context of DBS testing, are available. Villar et al. 36 , e.g., recorded almost equivalent elution capacities for all buffers used, but PBS/BSA 0.5% resulted in the lowest level of non-specific reactivity. A very similar observation was made by Croom and co-workers 44 when applying the specimen diluent of the Genetics Systems rLAV EIA for the elution of anti-HCV antibodies from DBS. Since the risk of sample degradation is exceedingly low in the first hours after preparation of DBS (see above), it was decided to incubate the spots O/N at ambient temperature and to support the elution process by gentle end-over-end mixing. This approach has the advantage that specimens punched out the previous day can be directly transferred to routine diagnostics early the next morning 23 . The volume of the elution buffer should be adapted to the minimal respective requirements of the assays used for subsequent analyses in order to keep the dilution factor as low as possible. However, a careful optimization of the elution conditions for every single analyte was not possible in the preceding evaluation because a high sample throughput had to be guaranteed in a comparatively short time during the "DRUCK Study" 17 . Consequently, the rather unfavorable volume of 1,000 µl of PBS-based buffer was used in order to complete the whole elution process for all parameters in two separate operations.
This approach one the one hand fails "completely in the anti-HBc/anti-HBs system for those individuals infected with HIV due to the low antibody concentrations; … and it required molecular biological procedures with optimal analytical sensitivity with regard to HBV DNA and HCV RNA tests." 17 On the other hand, the high elution volume proved to be in no way disadvantageous for the determination of HBsAg, anti-HCV, and anti-HIV by the kits used throughout the evaluation. "The detection of HBsAg positive materials from whole blood eluates succeeded with a sensitivity of 98.6% to a similarly high degree as in previous studies, which had in part used a much smaller elution volume of 100 µl, 250 µl, or 600 µl, or 500 µl"
